Ask about how you can participate in our open clinical trials and help pave the way for future advancements. Consider the possibilities and contribute to the health of your community.
Trial | Activation status | Disease site | Disease type | Phase | Biomarker/pathology |
---|---|---|---|---|---|
TPX-005-01 (TRIDENT-1) | Open | All solid tumors | Locally advanced or metastatic solid tumor | 1/2 | ALK or ROS1 positive or NTRK1/2/3 rearrangements |
AVANZAR | Open | Lung | Locally advanced or metastatic NSCLC | 3 | No actionable genomic alterations |
DESTINY LUNG04 (AZ) | Open | Lung | Locally advanced or metastatic NSCLC | 3 | HER2 mutations in Exon 19 or 20 |
ITEOS A2A-005 | Open | Lung | Locally advanced or metastatic non squamous NSCLC | 2 | |
LAWSON OCELOT | Open | Lung | Advanced NSCLC | 2 | EGFR activating mutation (excluding exon 20 insertions) |
TAS6417-301: Resilient3 | Opening soon | Lung | Locally advanced or metastatic non squamous NSCLC | 3 | EGFR exon 20 insertion |
MK-2870-004 | Opening soon | Lung | Advanced or metastatic non squamous NSCLC | 3 | EGFR mutations or ALK rearrangements or ROS1 rearrangements or RET rearrangements or BRAF V600E mutation or NTRK fusion or METx14 mutation |
BFAST | Open | Lung | Advanced or metastatic NSCLC | 2/3 | KRAS G12C positive |
JAVELIN MS100070-0119 | Open | Bladder | Locally advanced or metastatic urothelial cancer | 2 | |
MK-3475-365 | Opening soon | Prostate | Metastatic castration resistant prostate cancer | 1/2 | Adenocarcinoma without small cell histology |
REaCT-HOLD BMA (3CTN) | Open | Breast and prostate | Breast cancer and castrate resistant prostate cancer | 4 | |
SEAMARK (Pfizer) | Open | Colorectal | Metastatic colorectal cancer | 2 | BRAF V600E positive MSI-high MMR-deficient |
Roche CO44668 (IMbrave152) | Open | Liver | Advanced or metastatic hepatocellular carcinoma | 2 | |
MA.40 (FINER) - CCTG | Open | Breast and prostate | Breast cancer and castrate resistant prostate cancer | 4 | HER2 low ER positive and/or PR positive |
DYNASTY-Breast02 (Duality) | Opening soon | Breast | Advanced or metastatic breast cancer | 3 | HER2 low ER positive and/or PR positive |
MK V940-001 | Open | Skin/melanoma | Resected melanoma | 3 | |
TPX-005-01 (TRIDENT-1) | Open | All solid tumors | Locally advanced or metastatic solid tumor | 1/2 | ALK or ROS1 positive or NTRK1/2/3 rearrangements |
MK-2140-007 | On hold by sponsor | Lymphoid | Diffuse large B-cell lymphoma | 2 | |
Majestic 9 (64007957MMY3006) | Open | Myeloid | Multiple myeloma | 3 | |
Abbvie M20-621 | Open | Lymphoid | Diffuse large B-cell lymphoma | 3 | CD20 positive |